HB 6855 is a broad Department of Consumer Protection package that updates Connecticut’s drug control, cannabis, hemp, and pharmacy laws. A major portion of the bill tightens regulation of hemp flower and moderate-THC hemp products by limiting who may sell them, requiring age verification for purchasers and deliveries, imposing packaging and labeling rules, banning health or medical claims in advertising, and creating a registration system for moderate-THC hemp product vendors. It also gives the department enforcement authority, including administrative civil penalties, suspension, and revocation of registrations.
The bill also makes a wide set of changes to Connecticut’s cannabis framework. It creates a temporary cannabis operator license for court appointees managing cannabis businesses in court-supervised proceedings, requires standardized license-verification signage with a QR code, establishes a process for nonrenewal and reinstatement of lapsed cannabis establishment licenses, and revises application and ownership provisions for cannabis businesses, including rules affecting backers, key employees, equity joint ventures, and social equity-related fee structures. It further updates who may issue medical marijuana certifications, extends certification durations, allows certain temporary dispensary-issued certifications, and permits telehealth for certification and follow-up care.
In the pharmacy and controlled-substances sections, the bill strengthens oversight of nonresident pharmacies, especially those dispensing sterile compounded products, by requiring more detailed reporting, inspection documentation, and notice of disciplinary actions and recalls. It also updates Connecticut’s controlled substance scheduling provisions to align more closely with federal law in some respects while specifically adding or reaffirming control of several substances, including kratom, tianeptine, phenibut, nitazenes, bromazolam, synthetic cannabinoids, mephedrone, MDPV, and salvia-related compounds. The bill also makes technical changes to opioid-related statutory definitions and standing-order authority for opioid antagonists.
The overall sentiment reflected in the voting history was strongly favorable and largely noncontroversial. The bill received unanimous support in the General Law Committee and passed both chambers without any recorded opposition in the provided votes, suggesting broad agreement with the Department of Consumer Protection’s regulatory updates and the bill’s public-health and consumer-protection goals.
The main points of contention likely center on the bill’s tighter hemp and cannabis controls, especially the new registration requirements, sales restrictions, age-verification mandates, and advertising limits for hemp products, as well as the expanded authority over cannabis licensing and employee/backer oversight. The bill also touches on sensitive policy areas such as medical marijuana certification, telehealth prescribing, and the classification of substances like kratom and tianeptine, which could draw concern from hemp businesses, cannabis operators, medical providers, and consumers affected by the new restrictions.
The bill amends numerous sections of the Connecticut General Statutes governing consumer protection, controlled substances, pharmacy regulation, cannabis licensing, and hemp sales. It creates new regulatory requirements for moderate-THC hemp product vendors and hemp flower sales, revises cannabis establishment licensing and ownership rules, adds temporary licensing authority for court appointees, and updates nonresident pharmacy and sterile compounding oversight. It also changes controlled-substance scheduling and opioid-related definitions, with several provisions taking effect immediately and others phased in during 2025 and 2026.
The legislative sentiment appears overwhelmingly positive and bipartisan. The committee vote was unanimous, and both the House and Senate passed the bill 145-0 and 36-0, respectively. That voting pattern indicates broad support for the Department of Consumer Protection’s package and little visible floor-level opposition in the available record.
The most likely areas of disagreement are the bill’s regulatory tightening of hemp and cannabis markets. Hemp sellers and moderate-THC product vendors may object to the new registration regime, age-verification requirements, packaging limits, and restrictions on health claims, while cannabis businesses may scrutinize the new licensing, signage, renewal, and backer/key-employee rules. Medical marijuana stakeholders could also focus on the expanded role of dispensaries in issuing temporary certifications and the telehealth provisions, and some parties may question the decision to explicitly schedule substances such as kratom, tianeptine, phenibut, and nitazenes.